Advaxis Included in the Mentor Capital Cancer Immunotherapy Index Advaxis, Inc., the live, attenuated Listeria monocytogenes vaccine company, has been included in the Mentor Capital Cancer Immunotherapy Index, an index of companies judged noteworthy by Mentor Capital that are predominantly involved in the cancer immunotherapy sector. [Business Wire] Virax Announces Exclusive License with Transgene for Novel Skin Cancer Immunotherapeutic Treatment Australian bio-pharmaceutical company Virax Holdings Limited is pleased to announce that it has signed a worldwide exclusive License Agreement with leading French biopharmaceutical company Transgene for Virax to develop Transgene’s TG1042 a clinical-stage skin cancer immunotherapy product. [Virax Holdings Limited Press Release] Modell Chair in Pediatric Immunology Established The Children’s Hospital of Philadelphia announced the establishment of the Jeffrey Modell Endowed Chair in Pediatric Immunology Research. [The Children’s Hospital of Philadelphia Press Release] Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated with BPX-101 Cancer Vaccine Bellicum Pharmaceuticals, Inc. announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer, in three separate posters at the 2011 Genitourinary Cancers Symposium. [Bellicum Pharmaceuticals, Inc. Press Release] |